- LOGIN
- MemberShip
- 2026-05-15 21:38:02
- Company
- Pharmbio's Orafang was published in the JCC
- by Nho, Byung Chul Jul 13, 2022 06:05am
- Pharmbio (Chairman Nam Bong-gil) announced on the 12th that the comparative clinical results on the use of Orafang PO and 2L PEG drugs for IBD patients in Ccaid were introduced in the famous journal Journal of Cron's and Colitis. JCC is an SCIE-class medical journal in the field of inflammatory bowel disease published by Oxford University Press (OUP), and is a prestigious paper with an impact index of 9.485 over the past five years. In the paper, the comparative clinical results of the intestinal crystallinity (HCS) of the two preparations revealed that the intestinal tract of Orafang was significantly excellent in all compartments such as ascending colon (3.06
- Company
- Will Godex overcome its reimb crisis at half price?
- by Nho, Byung Chul Jul 13, 2022 06:05am
- Celltrion Pharm’s Godex cap, which was not recognized for its reimbursement adequacy and rejected reimbursement by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee on the 7th, is drawing attention due to the possibility of receiving a reimbursement cut rather than a reimbursement deletion decision. The reason why this speculation is gaining strength is that other drugs that contain the same main active ingredient as Godex - biphenyl dimethyl dicarboxylate (BDD)- such as Pharma King’s Nissel Tab and its 2-drug combo Pennel Cap (BDD+garlic oil) are still listed and recognized for reimbursement in Korea. Also, the current drug pricing regulations are based around a phased price reduction system that cuts the price of original drugs with the entry of generics, forcing reimbursement deletions or cuts after reevaluations with no other follow-ons in the market may be considered somewhat irrational. Therefore, the industry speculation is that Celltrion Pharm will overcome the current situation using a voluntary drug price cut, which would reduce the price of Godex to the level set for single and two-drug combo agents as its negotiation card during the objection period after demonstrating Godex’s efficacy and effect through literature and clinical data. Godex, a combination drug that contains BBD and 6 other ingredients, is currently listed at ₩371. The two-drug combo Pennel is listed at ₩312, and the single-agent drug Nissel at ₩144. Under the indication approved by the Ministry of Food and Drug Safety, Godex is used to treat liver disease with increased serum glutamic-pyruvic transaminase (SGPT), and Nissel and Pennel are used to treat chronic persisting hepatitis. Based on the indication, Godex may be considered to be different from Nissel or Pennel. However, the API used in all three drugs, BDD, is a standardized and synthesized derivative of schisandra chinensis (Omija) that rapidly lowers the liver inflammation GPT level with its antioxidant action and normalizes ALT with little rebound effect. In this broader sense, the three drugs can be considered to be in the same drug group. The sales performance of each drug last year amounted to ₩53.8 billion for Godex, ₩0.3 billion for Nissel, and ₩5.9 billion for Pennel. No latecomer of the combination drugs Godex and Pennel has been released yet due to difficulty securing subjects for bioequivalence tests, etc. Among single agent drugs, 23 products including Nissel are currently competing in the ₩4 billion market. HIRA aims to consolidate NHI finances using its reimbursement adequacy reevaluation standard to adjust items that cost ₩20 billion or more in claims (0.1% of the NHI claims amount). Using Nissel and Pennel as comparators for Godex also reflects HIRA's determination. Then, by how much would Celltrion Pharm need to lower Godex’s drug price to persuade HIRA? Celltrion Pharm would have two options. First, it could reduce the price of Godex to align with the price of the two-drug combination Pennel at ₩312. In this case, Godex’s price will fall 15.9% from its current price. The other option is to accept Nissel’s price, which is listed at ₩144, and attempt a blowout reduction in its price, lowering the price by 61%. When only considering the situation where Godex’s reimbursement adequacy was already rejected without regarding the current drug price regulation or rationality, using Nissel’s price for the voluntary price cut would be safer than using Pennel’s price to persuade the members of DREC. If Godex, which makes external sales of ₩60 billion, continues to sell the same after a 15.9% price cut, the drug can maintain its position as a blockbuster drug, bringing in ₩40 billion. However, with a 61% price cut, the drug’s sales will drop under the "claims of ₩20 billion or more" guideline that was set for reevalurationalehis time, and nullify any rational HIRA has to reject the proposition. Also, the fact that a new administrative notice has been issued for the "Rule for Standard of Medical Insurance Benefits of National Health Insurance" that stipulates the patent continuity as a factor for reimbursement reevaluations in addition to the existing standards such as clinical efficacy and drug pin overseas countries, may also act as a factor. If the continuity of a patent is applied as a new standard in the reevaluation, Celltrion Pharm would need to take into account the patent expired status of Godex even after demonstrating Godex’s efficacy and effect through literature and clinical data. In this case, it would be more advantageous to reduce the price of Godex to the price level of the single-agent drug rather than the two-drug combination. Regarding the overall situation, an industry official said, “If Celltrion Pharm and HIRA do not come to an agreement during the arbitration period, it can result in a lawsuit. And the court may accept the injunction to suspend the deletion of reimbursement, considering the current drug regulation and reevaluation conditions. However, rather than turning for the worst, the company may pursue a lesser evil method and work to increase sales after undergoing a reimbursement cut.”
- Opinion
- [Reporter's view] The 2nd Danaher, SD BioSensor
- by Jul 13, 2022 06:05am
- Danaher is considered one of the leading companies in the global diagnostic market along with Roche and Abbott. Danaher's growth engine, born in 1984, lies in aggressive M&A. So far, it has grown in size with more than 50 M&As. Rather than developing its own technology when entering a new market, it mainly used the method of acquiring promising companies and settling in the market with active management participation. It has grown into a comprehensive medical device company by acquiring companies in various fields such as molecular diagnostic company Cepheid, tooth implant manufacturing company Nobel Biocare, and diagnostic reagent company Beckman Coulter. Danaher didn't just focus on increasing the size of the company. All of Danaher's M&A activities are based on the company's business philosophy, DBS (Danaher Business System). Danaher established its own business system DBS in accordance with Japan's Kaizen principle, which means 'continuous improvement'. DBS measures companies or businesses to be acquired according to four principles: people, planning, process, and performance, and prepares and applies strategic plans after the acquisition. By successfully implementing this DBS system, Danaher was able to achieve overwhelming growth compared to its competitors. Companies that want to become the second Danaher have also appeared in Korea. It is the SD BioSensor in the domestic M&A market recently. After steadily focusing on diagnostic research, sales rose vertically due to COVID-19, recording 3 trillion won last year. Operating profit also reached 1.364 trillion won. As of the end of the first quarter, SD BioSensor's cash and cashable assets were 1.1636 trillion won. Since then, SD biosensors have launched aggressive M&As. Following the purchase of Brazilian diagnostic device distributor Eco Diagnostica for 47 billion won, it acquired Italian Relab and German Bestbion for 61.9 billion won and 16.1 billion won, respectively. And on the 8th, it also decided to acquire Meridian Bioscience, a U.S. diagnostic device company. It is the largest deal in the domestic pharmaceutical industry, with a total acquisition volume of 2 trillion won. Meridian Bioscience is considered a diagnostic device company that is strong in diagnosing digestive systems. SD BioSensor announced additional mergers and acquisitions this year. It showed its ambition to secure distribution networks in major global countries. Chairman Cho Young-sik of SD BioSensor announced such a plan and said, "We will increase various diagnostic device products such as STANDARD M10 and grow it into a global company that can compete with Danaher." This is not just a meaning of growing size by acquiring companies, but a willingness to establish a business philosophy to pave the way for growth as a global company. We hope that the domestic pharmaceutical bio industry will also establish its own philosophy and show that it is willing to invest. It is hoped that a domestic pharmaceutical bio environment will be established to strengthen internal stability, increase appearance, and compete globally.
- Policy
- Companies are worried about the result of Godex revaluation
- by Lee, Tak-Sun Jul 13, 2022 06:04am
- CelltrionThe result of the revaluation of Celltrion Pharmaceutical's Godex raised concerns for some pharmaceutical companies. This is because the re-evaluation results came out around the time the development of generics began in earnest. According to an industry on the 8th, some pharmaceutical companies are developing generic drugs for Godex. Godex contains seven ingredients, including ▲Biphenyl dimethyl dicarboxylate, ▲antitoxic silver ext., ▲Adenine HCl, ▲Pyridoxin HCl, ▲Riboflavin, and ▲Cyanocobalamin. Since it is a product that generates 70 billion won in annual performance, it was a product that had a strong desire to develop generic drugs. In particular, small and medium-sized companies have steadily challenged. It is known that some companies solved all raw material problems and completed development right before commercialization test. Other pharmaceutical companies also paid attention to the results of Godex's revaluation. The HIRA Pharmaceutical Benefit Evaluation Committee decided on the 7th that Godex was not eligible for benefits. It is a big deal for companies preparing generic drugs. Some companies have also been interested in developing tablets for Godex, a capsule formulation. This is because Celltrion Pharmaceutical was expected to defend generic drugs through tablet development. However, there is no news of permission for Godex, which has been approved in phase 3 clinical trials. Except for Godex's benefit, the HIRA's development of tablets is also likely to be disrupted. This is because, regardless of the formulation, products with the same ingredient have been determined to be non-reimbursement. Therefore, generic drugs also make it difficult to be reimbursed. An official from a company said, "I understand that some pharmaceutical companies have been seeking to develop generica for Godex for a long time." He expressed regret, saying, "I would have identified and planned the original defense strategy, but if the HIRA takes measures to delete the final benefit, all of this will be ruined." The crisis of Godex's deletion of benefit was not only a problem for Celltrion Pharmaceutical.
- Policy
- Hanall Biopharma's Glucofree OR is back
- by Lee, Tak-Sun Jul 12, 2022 05:53am
- Metformin OR products, which had been suspended due to the detection of excess NDMA of carcinogenic substances, are returning. Hanall Biopharma products have also returned to the reimbursed market with their names changed. With the emergence of them, competition is expected to intensify as the imbalance in supply and demand of Metformin OR is resolved. According to an industry on the 11th, Metformin OR products of Hanall Biopharma and Daewoong Bio have recently been lifted. The items are Hanall Biopharmas Glucofree OR 500mg, Glucofree OR 750mg, and Daewoong Bio's Diaformin XR 500mg and Diaformin XR 750mg. Hanall Biopharma's Glucofree OR is the name changed from Glucodown OR. Glucodown OR was the second highest-selling product in the Metformin single-product market after the original Diabex (Daewoong Pharmaceutical). In May 2020, manufacturing and sales of NDMA, a substance that is feared to cause cancer, were suspended because it exceeded the provisional management standards. Hanall Biopharma has been able to lift its manufacturing and sales suspension by changing it to an impurity-free product for about two years. Daewoong Bio's product, which was manufactured at the same factory and stopped manufacturing and selling together, has also returned. With the re-launch of the two products, worries about supply and demand can be eased, especially in the Metformin OR 750mg market. As the two products disappeared, Metformin OR 750mg was the only Metformin OR 750mg of Yuhan. Since the suspension of sales in 2020, the demand for Metformin OR 750mg has increased rapidly, making it difficult to supply it. 45 items in the Metformin OR 500mg market receive benefits. Hanall Biopharma and Daewoong Bio are also working to lift the suspension for 1000mg OR products. Before the suspension in 2020, Hanall Biopharma was the only competitive drug for imported Glucophage XR 1000mg and Diabex XR 100mg for domestic brands. Now, the number of competitive domestic drugs has increased as Dalim Biotech and Yuhan Corporation have newly entered. Hanall Biopharma and Daewoong Bio are members of Daewoong Pharmaceutical Group. Although Daewoong Pharmaceutical continues to rank No. 1 in the Metformin single-product market with its marketing import Diabex, its own production items of Hanall Biopharma and Daewoong Bio are also strategically important. This is because it is necessary to maintain the overwhelming market share of Daewoong Pharmaceutical Group while being a domestically produced product that can check imported items. Metformin preparation is the primary essential drug for patients with secondary diabetes. As a result, it is expected that Yuhan and Dalim will compete fiercely with Hanall Biopharma and Daewoong Bio for the first place as they are growing high in the single market of Metformin after the suspension of sales.
- Company
- Vyzulta reimbursed and prescribed at general hospitals
- by Eo, Yun-Ho Jul 12, 2022 05:53am
- The glaucoma treatment ‘Vyzulta’ has received approval for insurance benefits and is landing at general hospitals in Korea. According to industry sources, Baush + Lomb Korea’s ophthalmic solution Vyzulta (latanoprostene bunod) has passed the drug committees of various medical institutions including the Seoul National University Hospital and Gangnam Severance Hospital. Vyzulta, which was approved in Korea in February last year, passed the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee (DREC) deliberations in the August of the same year and was listed for reimbursement starting February this year. Vyzulta is an ophthalmic solution that reduces intraocular pressure (IOP), which is a risk factor of glaucoma, and is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Drug treatment to reduce IOP is currently considered the most effective treatment for glaucoma. Vyzulta has two separate MOAs for drainage and is metabolized into two moieties1 – its API Latanoprost acid and nitric oxide –to reduce IOP through by increasing the outflow of aqueous humor through both uveoscleral and trabecular meshwork channels Also, Vyzulta demonstrated a superior mean IOP reduction effect over latanoprost 0.005%, a common glaucoma treatment, and demonstrated statistically significantly greater mean IOP reduction over Timolol 0.5% in clinical trials. Meanwhile, Vyzulta’s had costed around ₩110,000 per year without reimbursement, but the patient’s out-of-pocket cost was reduced to around ₩30,000 per year with reimbursement, being applied a 30% coinsurance rate.
- Company
- Johnson & Johnson Medical Devices changed its name
- by Eo, Yun-Ho Jul 12, 2022 05:53am
- Director Oh Jin-yong Johnson & Johnson Medical of Korea announced a new start with a change of name. The company held a press conference explaining the "J&J MedTech" rebranding at The Plaza Hotel in Jung-gu, Seoul on the 11th and announced its vision to lead innovation in the future medical market combined with digital as a global leading company. Johnson & Johnson's medical device division, a U.S.-based global healthcare company, changed its name from Johnson & Johnson Medical Devices to Johnson & Johnson MedTech in March. The name of the Korean branch will be maintained by the existing Johnson & Johnson Medical Center. The event was announced by Oh Jin-yong, president of North Asia, and introduced a new corporate vision and business direction focusing on digital transformation. President Oh pointed out the recent rapid development of digital transformation throughout the industry, and in line with this, Johnson & Johnson Medical Korea will make a new leap forward as a medtech company that encompasses not only medical devices but also digital solutions such as robotic surgery and medical software. As a specific strategy, it plans to develop new models of future healthcare in the digital era, contribute to improving human health through state-of-the-art technology and innovation, and present integrated solutions for optimal treatment away from existing products to focus on overall health. "The transition to &J MedTech is part of efforts to provide innovative treatment solutions to meet the rapidly digitizing medical environment and patient demand. "Our vision is to provide smarter, less invasive, and more customized treatment for patients by utilizing advanced technologies such as AI, machine learning, data science, and virtual reality," he said. To this end, three future directions were presented, leading the healthcare innovation, developing digital healthcare solutions that encompass the entire process of patient treatment, and optimal treatment using data science. It will also continue to cooperate closely with medical personnel to reflect the demand of clinical sites and to create a better medical environment. President Oh Jin-yong said, "The Korean medical device market is emerging as a center of Meditec innovation in the Asia-Pacific region thanks to continuous growth and the emergence of ventures with innovative technologies and global competitiveness." Johnson & Johnson Medical Korea is a global company that has provided medical devices and digital solutions for 34 years since its establishment in 1988, and consists of major business units such as ETHICON, which provides surgical medical devices and digital solutions, DePuy Syntes, and CSS (Cardiovascular & Specialty Solutions).
- Company
- NPS buys Samsung Biologics and SD Biosensor shares
- by Kim, Jin-Gu Jul 12, 2022 05:52am
- In the midst of the prolonged contraction observed in the Korean stock market, Korea’s largest institutional investor, the National Pension Service (NPS), was found to have expanded its investment in biotech/pharma companies by nearly ₩500 billion. NPS net purchased ₩140 billion worth of Samsung Biologics shares and increased investment in SD Biosensor, Celltrion, Hanmi Pharmaceutical, Celltrion Healthcare, and Daewoong Pharmacuetical by over ₩50 billion. Also, NPS net sold over ₩50 billion worth of Yuhan Corp’s shares and over ₩40 billion worth of SK Bioscience shares during the same period. ◆NPS increases investment in Samsung Biologics and SD Biosensor again this year… turns to net purchases from net selling According to the Korea Exchange on the 11th, NPS net sold ₩417.3 billion worth of shares in the domestic securities market and the KOSDAQ market in the first half of this year. However, no large-scale net sales like the ones made last year were observed. Last year, NPS had net sold shares worth ₩2.4 trillion after deciding to curtail local equity exposure to 16.8%. In the Pharma/Bio industry, NPS was found to have made more purchases than sales. It sold a total of ₩2.43 trillion and bought ₩2.89 trillion, resulting in net sales of ₩459.2 billion. In particular, NPS increased investment in Samsung Biologics, SD Biosensor, Celltrion, Hanmi Pharmaceutical, Celltrion Healthcare, and Daewoong Pharmacuetical by over ₩50 billion. NPS net purchased Samsung Biologics shares worth around ₩140.1 billion in only the first half of this year. This is analyzed to be NPS’s decision to continuously expand investment in Samsung Biologics this year. NPS had net bought ₩917.9 billion shares of Samsung Biologics’ stocks last year. NPS is also continuously increasing investment in SD Biosensor and had net purchased shares worth ₩95.3 billion in the first half of this year. NPS had net purchased ₩124.3 billion worth of SD Biosensor’s shares last year. In addition, NPS had net purchased over ₩70 billion worth of shares in Celltrion, Hanmi Pharmaceutical, and Celltrion Healthcare each in the first half of this year. The institution’s decision to purchase Celltrion’s shares again is a focus of interest as it had net sold ₩648.6 billion of Celltrion’s shares last year. NPS had net sold over ₩600 billion last year and then turned to net purchase over ₩70 billion in the first half of this year. NPS had also net purchased shares over ₩10 billion in 18 companies including Daewoong Pharmacuetical, ST Pharm, SK Biopharmaceuticals, Hanmi Science, Lutronic, Osten Implant, Daewoong, GC Pharma, Jeisys Medical, Dentium, Ray Pharma, PharmaResearch, and Pharmicell. ◆NPS net buys ₩280 billion of SK Bioscience shares last year but net sells ₩43 billion in 2022 1H On the other hand, NPS sold a large number of shares it owned in Yuhan Corp, SK Bioscience, Bukwang Pharmaceutical, Mezzion, Hugel, and GC Cell. In particular, SK Bioscience and GC Cell moved from the top net bought shares last year to the top net sold shares in the first half of this year. In the case of Yuhan Corp, NPS bought ₩86.2 billion and sold ₩140.3 billion in 1H this year, resulting in net sales worth ₩54.1 billion. Also, NPS net sold ₩43 billion worth of SK Bioscience’s shares in the first half of this year. This is in stark contrast to how the company net bought ₩280.3 billion last year. Also, NPS net purchased ₩112.2 billion last year, but net sold ₩11.9 billion of SK Bioscience’s shares in the first half of this year. NPS also net sold over ₩10 billion worth of shares from Bukwang Pharmaceutical (₩26.5 billion), Mezzion (₩19.8 billion), and Hugel (₩19.3 billion).
- Company
- Will Celltrion Pharmaceutical voluntarily cut down on Godex?
- by Nho, Byung Chul Jul 12, 2022 05:52am
- Celltrion Pharmaceutical's Godex is on the verge of being expelled from insurance registration, and it is expected to cut voluntary drug prices at the level of comparative drugs as the last defense measure to maintain benefits. The reason why Celltrion Pharmaceutical's strategy is drawing attention is that if Godex, which looks like 60 billion won, is deleted, it is inevitable to lose about 20% of its total sales, which is expected to make every effort to maintain insurance drugs through clinical utility proof. Godex was not recognized for the appropriateness of the benefit at the 7th review of the Pharmaceutical Benefit Evaluation Committee held on the 7th, but the final results may change depending on the evaluation of the objection. This re-evaluation project is planned for five years from 2021 to 2025, and it is difficult to overcome obstacles in this way because it contains more than 20 billion won, or less than one country among A8 countries, or drugs pointed out by the committee due to insufficient policy, social needs and usefulness. It is insufficient to judge the HIRA's expression of its willingness to derive reasonable drug prices by comparing clinical usefulness and drug prices in excluded countries with domestic released drugs as simply proof of usefulness. The most effective means is the voluntary reduction of drug prices to the level of a single drug (or Pennel Cap ( 312 won ) with the same main ingredient). Godex capsules contain 25mg of Biphenyl Dimethyl Dicarboxylate, 500μg of Riboflavin, 125μg of Cyanoborate, 2.5mg of Adenine HCl, 25mg of Pyridoxynate, and 150mg of Carnitine Orotate. A comparative drug with the same main ingredient is Pharmaking's Nissel (144 won). Despite the expiration of Godex patents, many pharmaceutical bio companies failed to release generics because they could not successfully derive biological equivalence test data for other auxiliary substances except biphenyl dimethyl Dicharboxylate, the main ingredient. It is true that even though Godex is a composite agent, if the drug price is the same as the single drug Nissel by giving up the drug price value for the rest of the ingredient combination except for the main ingredient, the HIRA lacks the reasonable logic to prevent it. Sales of Godex could be halved due to a benefit cut of 371 won → 144 won, but it can actually prevent it from leaving the market and restore it to its original state according to its sales strategy, which is likely to reduce its weakness. It is logical that Celltrion Pharmaceutical's the HIRA limit is unfair to reduce the benefit of Godex capsules, a composite drug, at a time when insurance registration and benefits continue due to the clear effect of a single product. In addition, under the current regulations, drug prices fall only when generics enter, but there is a logic that it is unreasonable to target them for re-evaluation even though generics has not been released.
- Policy
- Reimbursement of new migraine drugs gain momentum
- by Lee, Tak-Sun Jul 11, 2022 06:04am
- New migraine drug Reyvow receives conditional approval from the DREC on the 7th New migraine drug Reyvow receives conditional approval from the DREC on the 7th New migraine drugs are competitively pushing to receive reimbursement listing in Korea. Following Lilly’s ‘Emgality (galcanezumab)’ in May, Ildong Pharmamceutical’s ‘'Reyvow (lasmiditan)’ has also passed deliberations by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee (DREC) on the 7th. With Emgality already in pricing negotiations with the National Health Insurance Service, Il Dong is also working to speed up the listing process for Reyvow. Also, Teva-Handok’s new migraine drug ‘Ajovy’ is being reviewed for reimbursement adequacy. The industry analysis is that all 3 new migraine drugs may be reimbursed within the year. Reyvow passed DREC review in only 2 months after it received approval in May through the approval-assessment linkage system. This is evidence that its importer and seller, Ildong Pharmaceuticals, is making efforts to speed up Reyvow’s reimbursement process. Therefore, if the price level presented by DREC close to the company’s estimate, the two parties may immediately begin pricing negotiations. Reyvow selectively inhibits serotonin 5-HT 1F receptor. Triptan-class drugs, which are most commonly used for migraines also work on serotonin but may constrict the blood vessels and cause cardiovascular diseases such as myocardial infarction, strokes, etc. On the other hand, Reyvow, a selective inhibitor, has the advantage of causing fewer cardiovascular side effects. If a patient has difficulty receiving triptans due to side effects, Reyvow would rise as a viable option. Also, both the triptans and Reyvow come in tablet formulations. The other two, Emgality and Ajovy, are injection-type formulations. Both are humanized monoclonal antibody drugs that bind to the CGRP ligand that plays a key role in inducing migraine symptoms to inhibit its binding to its receptor. Therefore, the drugs are known to cost millions of won per year, much more expensive than the existing drugs. This is why the listing price of Emgality and Ajovy is also the focus of attention. Existing triptan class drugs are listed at 3,000 to 4,000 won per tablet, but the price of Emgality and Ajovy will have to be much higher than triptans as they use a different mechanism of action to improve treatment effect. Their formulation, as injection-type drugs, also differs from triptans. However, like triptans, Reyvow is a tablet formulation that acts on serotonin, therefore the price of the listed triptan class drugs may be used as a reference in Reyvow’s pricing. With Emgality at the forefront of the listing process, Teva and Ildong will first be keenly eyeing what price will be set for Emgality. As Teva has applied to hold a briefing session on Ajovy for HIRA reviewers, its reimbursement is also expected to be deliberated by DREC soon. The Korean migraine treatment market has remained small compared to its patient size. Accoring to UBIST in 2020, annual prescriptions of triptan-class drugs were at a 15.5 billion won range. However, the prevalence rate of migraines in Korea is 6%. According to HIRA's statistics, 550,000 patients received medical treatment for migraines, but around 2 million patients are estimated to have not visited hospitals or clinics for their condition in 2020. Therefore, the release of new drugs in the field is expected to further increase the market size.
